PATENT CLAIM ANALYSIS

Application Number: 16091432
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "641000"]

Abstract:
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic acid (20:5; EPA), or esters thereof, (iii) choline, or salts or esters thereof, in the manufacture of a product for therapeutically treating or preventing global developmental delay or reducing the risk symptoms such as cognitive impairment associated therewith in a child.

Claim (Index 33):
The method according to  claim 26 , further comprising assessing the child at the scale of the Bayley III test.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 97.0
- Lexical Diversity: 1.64407
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15417943', '14005098', '15770116', '15115487', '14421432']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.70046192761076
- 35 USC 102 Novelty (BERT): 0.5277497342845046
- Combined Prediction Score: 0.6831907082781346
- Mean Citation Score: 213.514056
- Max Citation Score: 227.81703
- Similarity Product: 102.9004650523746

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test